Cardiol Therapeutics Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-13upcoming | -0.10 | — | — |
| 2026-05-11 | -0.09 | -0.10 | -11.11% |
| 2026-03-31 | -0.11 | -0.07 | +36.36% |
| 2025-11-13 | -0.10 | -0.12 | -14.29% |
| 2025-08-14 | -0.12 | -0.10 | +18.92% |
| 2025-05-14 | -0.13 | -0.10 | +23.08% |
| 2025-03-31 | -0.12 | -0.09 | +22.86% |
| 2024-11-14 | -0.11 | -0.18 | -58.83% |
| 2024-08-12 | -0.13 | -0.10 | +21.05% |
| 2024-05-14 | -0.10 | -0.14 | -33.33% |
| 2024-04-01 | -0.12 | -0.12 | — |
| 2023-11-14 | -0.12 | -0.09 | +25.00% |
| 2023-08-10 | -0.12 | -0.12 | +4.00% |
| 2023-05-15 | -0.15 | -0.11 | +26.67% |
| 2023-03-28 | -0.15 | -0.11 | +29.03% |
| 2022-11-10 | -0.14 | -0.13 | +10.34% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| CRDL | -10.95% | +20.79% | +27.88% | -2.40% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -13.92% | +25.43% | +31.33% | -15.09% |